The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
The origin of NMDA receptor hypofunction in schizophrenia
Open accessAbstract
N-methyl-d-aspartate (NMDA) receptor (NMDAR) hypofunction plays a key role in pathophysiology of schizophrenia. Since NMDAR hypofunction has also been reported in autism, Alzheimer’s disease and cognitive dementia, it is crucial to identify the location, timing, and mechanism of NMDAR hypofunction for schizophrenia for better understanding of disease etiology and for novel therapeutic intervention. In this review, we first discuss the shared underlying mechanisms of NMDAR hypofunction in NMDAR antagonist models and the anti-NMDAR autoantibody model of schizophrenia and suggest that NMDAR hypofunction could occur in GABAergic neurons in both models. Preclinical models using transgenic mice have shown that NMDAR hypofunction in cortical GABAergic neurons, in particular parvalbumin-positive fast-spiking interneurons, in the early postnatal period confers schizophrenia-related phenotypes. Recent studies suggest that NMDAR hypofunction can also occur in PV-positive GABAergic neurons with alterations of NMDAR–associated proteins, such as neuregulin/ErbB4, α7nAChR, and serine racemase. Furthermore, several environmental factors, such as oxidative stress, kynurenic acid and hypoxia, may also potentially elicit NMDAR hypofunction in GABAergic neurons in early postnatal period. Altogether, the studies discussed here support a central role for GABAergic abnormalities in the context of NMDAR hypofunction. We conclude by suggesting potential therapeutic strategies to improve the function of fast-spiking neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Redox modulation of synaptic responses and plasticity in rat CA1 hippocampal neurons
Bernard, C., Hirsch, J. C., Khazipov, R., Ben‐Ari, Y., & GOZLAN, H. (1997) · Experimental Brain Research · doi:10.1007/bf02450332 · Cited by 33
In vitro neuronal network activity in NMDA receptor encephalitis
Jantzen, S., Ferrea, S., Wach, C., Quasthoff, K., Illes, S., Scherfeld, D., Hartung, H., Seitz, R. J., & Dihné, M. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-17 · Cited by 33
Chen, C., Cheng, M.-C., Liu, C., Liu, C., Lin, K.-H., & Hwu, H. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.03.012 · Cited by 33
Anti-NMDA receptor antibodies in patients with a first episode of schizophrenia
Vališ, M., Masopust, J., Andrýs, C., Bažant, J., Vyšata, O., & Kuča, K. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s80746 · Cited by 32
Frederiksen, K., Lu, D., Yang, J., Jensen, H. S., Bastlund, J. F., Larsen, P. H., Liu, H., Crestey, F., Dekermendjian, K., Badolo, L., et al. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13626 · Cited by 31
Schmitt, A., Fendt, M., Zink, M., Ebert, U., Starke, M., Berthold, M., Herb, A., Petroianu, G. A., Falkai, P., & Henn, F. A. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0440-7 · Cited by 31
Flores-Barrera, E., Thomases, D. R., Cass, D. K., Bhandari, A., Schwarcz, R. M., Bruno, J. P., & Tseng, K. Y. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0932-17.2017 · Cited by 31
Kotzadimitriou, D., Nissen, W., Paizs, M., Newton, K., Harrison, P. J., Paulsen, O., & Lamsa, K. P. (2018) · eNeuro · doi:10.1523/eneuro.0418-17.2018 · Cited by 31
Shelkar, G. P., Pavuluri, R., Gandhi, P. J., Ravikrishnan, A., Gawande, D. Y., Liu, J., Stairs, D. J., Ugale, R. R., & Dravid, S. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-43957-2 · Cited by 31
Batterman, K. V., & Bucci, D. J. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.08.014 · Cited by 30
Murakami, K., Ishikawa, Y., & Sato, F. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.024 · Cited by 27
Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III
Olaya, J. C., Heusner, C. L., Matsumoto, M., Weickert, C. S., & Karl, T. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.03.026 · Cited by 27
Hou, G., & Zhang, Z. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00353 · Cited by 23
Colocalization of distinct NMDA receptor subtypes at excitatory synapses in the entorhinal cortex
Beesley, S., Sullenberger, T., Pilli, J., Abbasi, S., Gunjan, A., & Kumar, S. S. (2018) · Journal of Neurophysiology · doi:10.1152/jn.00468.2018 · Cited by 17
Gu, X., & Lü, W. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.01.024 · Cited by 11
Gene-Environment Interaction in a Conditional NMDAR-Knockout Model of Schizophrenia
Bygrave, A. M., Masiulis, S., Kullmann, D. M., Bannerman, D. M., & Kätzel, D. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00332 · Cited by 9
Is the prevalence of anti-N-methyl-d-aspartate receptor antibodies in schizophrenia overestimated?
Nakagami, Y., Sugihara, G., Ikeda, A., & Murai, T. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.007 · Cited by 4
Cited by
Flavonoids and their role in oxidative stress, inflammation, and human diseases
Jomova, K., Alomar, S. Y., Valko, R., Liska, J., Nepovimova, E., Kuca, K., & Valko, M. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111489 · Cited by 362
The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking
Phadke, R. A., Brack, A., Fournier, L. A., Kruzich, E., Sha, M., Picard, I., Johnson, C., Stroumbakis, D., Salgado, M., Yeung, C., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-024-02701-7 · Cited by 20
Janz, P., Bainier, M., Marashli, S., Schoenenberger, P., Valencia, M., & Redondo, R. L. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02224-1 · Cited by 18
Metadata
- Authors
- Nakazawa, K., & Sapkota, K.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 205
- Pages
- 107426
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2980754671
- Cited by
- 275
- References
- 217
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.